Compare NATL & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | RARE |
|---|---|---|
| Founded | 2023 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | N/A | 2014 |
| Metric | NATL | RARE |
|---|---|---|
| Price | $40.32 | $22.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $42.75 | ★ $73.11 |
| AVG Volume (30 Days) | 353.9K | ★ 4.0M |
| Earning Date | 03-02-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,322,000,000.00 | $630,598,000.00 |
| Revenue This Year | $2.83 | $19.68 |
| Revenue Next Year | $3.96 | $19.44 |
| P/E Ratio | $22.94 | ★ N/A |
| Revenue Growth | 0.63 | ★ 20.63 |
| 52 Week Low | $22.30 | $18.41 |
| 52 Week High | $42.23 | $46.50 |
| Indicator | NATL | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 34.87 |
| Support Level | $39.08 | $22.40 |
| Resistance Level | $41.01 | $24.65 |
| Average True Range (ATR) | 1.09 | 1.53 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 75.87 | 64.17 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.